Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Statement for Appropriate Clinical Use of PCSK9 Inhibitors.

Literature DB >> 29899173

Statement for Appropriate Clinical Use of PCSK9 Inhibitors.

Atsushi Nohara¹, Hirotoshi Ohmura², Hiroaki Okazaki³, Masatsune Ogura⁴, Kazuo Kitagawa⁵, Masahiro Koseki⁶, Kayoko Sato⁷, Kazuhisa Tsukamoto⁸, Shizuya Yamashita^9,10.

Abstract

Entities: Chemical Disease Gene Species

Keywords: Appropriate Clinical Use; PCSK9 Inhibitors; Statement

Mesh：

Substances：

Year: 2018 PMID： 29899173 PMCID： PMC6099074 DOI： 10.5551/jat.45229

Source DB: PubMed Journal: J Atheroscler Thromb ISSN： 1340-3478 Impact factor: 4.928

× No keyword cloud information.

5 in total

1. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).

Authors: Marc P Bonaca; Patrice Nault; Robert P Giugliano; Anthony C Keech; Armando Lira Pineda; Estella Kanevsky; Julia Kuder; Sabina A Murphy; J Wouter Jukema; Basil S Lewis; Lale Tokgozoglu; Ransi Somaratne; Peter S Sever; Terje R Pedersen; Marc S Sabatine
Journal: Circulation Date: 2017-11-13 Impact factor: 29.690

2. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

Authors: Ulf Landmesser; M John Chapman; Jane K Stock; Pierre Amarenco; Jill J F Belch; Jan Borén; Michel Farnier; Brian A Ference; Stephan Gielen; Ian Graham; Diederick E Grobbee; G Kees Hovingh; Thomas F Lüscher; Massimo F Piepoli; Kausik K Ray; Erik S Stroes; Olov Wiklund; Stephan Windecker; Jose Luis Zamorano; Fausto Pinto; Lale Tokgözoglu; Jeroen J Bax; Alberico L Catapano
Journal: Eur Heart J Date: 2018-04-07 Impact factor: 29.983

3. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors: Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal: N Engl J Med Date: 2017-03-17 Impact factor: 91.245

4. Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia.

Authors: Mariko Harada-Shiba; Katsunori Ikewaki; Atsushi Nohara; Yoshihiko Otsubo; Koji Yanagi; Masayuki Yoshida; Qing Chang; Pamela Foulds
Journal: J Atheroscler Thromb Date: 2017-02-02 Impact factor: 4.928

5. Guidance for Pediatric Familial Hypercholesterolemia 2017.

Authors: Mariko Harada-Shiba; Takao Ohta; Akira Ohtake; Masatsune Ogura; Kazushige Dobashi; Atsushi Nohara; Shizuya Yamashita; Koutaro Yokote
Journal: J Atheroscler Thromb Date: 2018-02-06 Impact factor: 4.928

5 in total

4 in total

Review 1. Appropriate Use of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Atherosclerotic Cardiovascular Disease: Comparison of Recommendations from Different Guidelines or Consensus Around the World.

Authors: Jia-Ling Lin; Po-Hsun Huang; Hung-I Yeh; Yi-Heng Li
Journal: Acta Cardiol Sin Date: 2020-09 Impact factor: 2.672